Skip to main content
Figure 2 | Molecular Cancer

Figure 2

From: Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo

Figure 2

Basal level expression of survivin and Cox-2 proteins in various cancer cell lines and effect of p53 and p21. In (A), the various cancer cell lines were cultured in the absence of any drug treatment, harvested in log phase, and analyzed by Western blot analysis with antibodies to survivin, cycloxygenase-2 (Cox-2), and actin (as a loading control). In addition, the p53 status of each line (as reported in a variety of reports) is indicated (wt: wild type; m: mutant). (Note that in LN229 cells, wt p53 function is retained, despite a mutation in the coding sequence.) In (B), three variants of HCT116 colon carcinoma cells were treated with celecoxib (Cxb) or DMC and analyzed by Western blot analysis for survivin levels and actin (as a loading control; only one representative panel is shown). The top panel shows results with HCT116 cells that harbor wild type alleles of the p53 and p21 genes; the second panel is from cells with disrupted p53 alleles (p53-/-); the third panel is from cells lacking p21 (p21-/-).

Back to article page

Molecular Cancer

ISSN: 1476-4598